Previous close | 35.48 |
Open | 36.84 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 35.49 - 36.84 |
52-week range | 23.72 - 37.57 |
Volume | |
Avg. volume | 178,054 |
Market cap | 68.589B |
Beta (5Y monthly) | 0.29 |
PE ratio (TTM) | 54.20 |
EPS (TTM) | 0.66 |
Earnings date | 29 Jul 2024 - 02 Aug 2024 |
Forward dividend & yield | 0.24 (0.69%) |
Ex-dividend date | 28 Sept 2023 |
1y target est | N/A |
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.